Deleted in liver cancer-1 (DLC-1): A tumor suppressor not just for liver

Yi Chun Liao, Su Hao Lo

Research output: Contribution to journalArticlepeer-review

97 Scopus citations


Deleted in liver cancer 1 (DLC-1), as its name implied, was originally isolated as a potential tumor suppressor gene often deleted in hepatocellular carcinoma. Further studies have indicated that down-expression of DLC-1 either by genomic deletion or DNA methylation is associated with a variety of cancer types including lung, breast, prostate, kidney, colon, uterus, ovary, and stomach. Re-expression of DLC-1 in cancer cells regulates the structure of actin cytoskeleton and focal adhesions and significantly inhibits cell growth, supporting its role as a tumor suppressor. This tumor suppressive function relies on DLC-1's RhoGTPase activating protein (RhoGAP) activity and steroidogenic acute regulatory (StAR)-related lipid transfer (START) domain, as well as its focal adhesion localization, which is recruited by the Src Homology 2 (SH2) domains of tensins in a phosphotyrosine-independent fashion. Therefore, the expression and subcellular localization of DLC-1 could be a useful molecular marker for cancer prognosis, whereas DLC-1 and its downstream signaling molecules might be therapeutic targets for the treatment of cancer.

Original languageEnglish (US)
Pages (from-to)843-847
Number of pages5
JournalInternational Journal of Biochemistry and Cell Biology
Issue number5
StatePublished - 2008


  • DLC
  • Focal adhesion
  • Tumor suppressor

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology


Dive into the research topics of 'Deleted in liver cancer-1 (DLC-1): A tumor suppressor not just for liver'. Together they form a unique fingerprint.

Cite this